Home

Alfonso G Zulueta

CIK 1596336 · SVP & President, Lilly Int'l · last filed 2025-11-10

Alfonso G Zulueta is a SVP & President, Lilly Int'l who has filed 49 SEC Form 4 insider transactions across 5 companies since 2014. The most recent filing, for CTS, was dated Nov 10, 2025. Across all open-market trades the lifetime net is −$17.6M, making them a net seller over the disclosed history. Current disclosed insider exposure totals $72.9M across reported positions. 34 SEC filings were submitted jointly with LILLY & Co ELI.

"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.

Loading insider history…
Disclosed Exposure

$72.87M

Companies

5

Total Filings

49

Lifetime Open-Market Net

-$17.62M

Filer Profile

Reported Address
4925 INDIANA AVE
LISLE, IL 60532
Related Filers
LILLY & Co ELI — 34 joint filings, latest 2021-02-10
Profile details as reported on the filer's SEC submissions — for individual insiders the address is often in care of the issuer. Related filers are identified from jointly filed SEC submissions and shared reported addresses. View filings on SEC EDGAR.

Holdings By Company

Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
Symbol Role Shares Price Disclosed Exposure Lifetime OM Net Filings Latest Filed
CTS Director 35,913 $57.18 $2.05M $99.6K 10 2025-11-10
Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Director 133,301 $0.01 $773 $0 1 2024-01-04
Syneos Health, Inc. (SYNH) Delisted Director 4,863 $42.98 $209.0K $0 4 2023-09-28
AMRN Director — $13.63 — $0 2 2022-06-29
LLY SVP & President, Lilly Int'l 61,614 $1149.36 $70.82M -$17.72M 32 2021-02-10

Recent Filings

49 filings
Insider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
Filed Symbol Action Net Shares Net $ Link
2025-11-10 CTS Grant (A) +3,500 $0 EDGAR
2024-11-08 CTS Grant (A) +2,400 $0 EDGAR
2024-01-04 Calidi Biotherapeutics, Inc. (CLDI.WS) Delisted Grant (A) +5,644 $10.2K EDGAR
2023-11-06 CTS Grant (A) +3,600 $0 EDGAR
2023-09-28 Syneos Health, Inc. (SYNH) Delisted Disp (D) −8,356 -$150.2K EDGAR
2023-05-30 Syneos Health, Inc. (SYNH) Delisted Grant (A) +4,863 $0 EDGAR
2022-11-14 CTS Grant (A) +3,100 $0 EDGAR
2022-06-29 AMRN Grant (A) — $0 EDGAR
2022-05-27 Syneos Health, Inc. (SYNH) Delisted Grant (A) +2,839 $0 EDGAR
2022-05-20 AMRN Grant (A) — $0 EDGAR
Showing 1–10 of 49
Page 1 of 5
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.